Keith T Flaherty
Overview
Explore the profile of Keith T Flaherty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
391
Citations
42214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gouda M, Wei Z, Rodon J, Davies M, Janku F, Gray R, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400451.
PMID: 39913886
Purpose: Copanlisib, a pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with activity predominantly against the PI3K-delta and PI3K-alpha isoforms, has shown promising results in preclinical cancer models with PTEN loss. Herein, we...
2.
Schadendorf D, Dummer R, Flaherty K, Robert C, Arance A, de Groot J, et al.
Future Oncol
. 2025 Jan;
21(5):523-531.
PMID: 39810544
No abstract available.
3.
Sun Y, Maggs L, Panda A, Wright S, Cicerchia A, Jenney A, et al.
Cancer Immunol Res
. 2025 Jan;
13(2):210-228.
PMID: 39785827
Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute...
4.
Zauderer M, Jegede O, Jackman D, Zwiebel J, Gray R, Wang V, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400327.
PMID: 39693587
Purpose: The NCI-MATCH trial assigned patients with solid tumors, lymphomas, or multiple myeloma to targeted therapies on the basis of identified genetic alterations from tumor biopsies. In preclinical models, ()-inactivated...
5.
Gien L, Song Z, Poklepovic A, Collisson E, Zwiebel J, Gray R, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400514.
PMID: 39666929
Purpose: The NCI-MATCH study is a tumor-agnostic platform trial enrolling patients to targeted therapies on the basis of genomic alterations. Subprotocol V investigated sunitinib in patients with tumors harboring -...
6.
Tarantino G, Ricker C, Wang A, Ge W, Aprati T, Huang A, et al.
Sci Adv
. 2024 Nov;
10(48):eadp4670.
PMID: 39602539
The introduction of immune checkpoint blockade (ICB) has markedly improved outcomes for advanced melanoma. However, many patients develop resistance through unknown mechanisms. While combination ICB has improved response rate and...
7.
OHara M, Jegede O, Dickson M, DeMichele A, Piekarz R, Gray R, et al.
Clin Cancer Res
. 2024 Oct;
31(1):56-64.
PMID: 39437014
Purpose: Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy...
8.
Duan H, Xie Y, Wu S, Zhao G, Zeng Z, Hu H, et al.
J Transl Med
. 2024 Sep;
22(1):880.
PMID: 39350123
Background: Patients with glioblastoma (GBM) have a poor prognosis and limited treatment options. The mRNA decapping enzyme scavenger (DCPS) is a cap-hydrolyzing enzyme. The DCPS inhibitor RG3039 exhibited excellent central...
9.
Wei S, Du K, Lan H, Yang Z, Deng Y, Wei Z, et al.
bioRxiv
. 2024 Sep;
PMID: 39314469
Statement Of Translational Relevance: This study paves the way for the creation of innovative therapeutic strategies, aimed at subverting resistance to immune checkpoint blockade (ICB) therapies in metastatic melanoma patients....
10.
Rodriguez L, Gormley N, Lu R, Amatya A, Demetri G, Flaherty K, et al.
Clin Cancer Res
. 2024 Jul;
30(18):3974-3982.
PMID: 39037364
Advances in anticancer therapies have provided crucial benefits for millions of patients who are living long and fulfilling lives. Although these successes should be celebrated, there is certainly room to...